Onxeo: Combined Ordinary and Extraordinary General Meeting on April 15, 2015

Regulatory News:

Onxeo’s (Paris:ONXEO) (NASDAQ OMX:ONXEO) shareholders are invited to attend the Combined Ordinary and Extraordinary General Meeting to be held at 9:30am on April 15, 2015 at the company's head office (49 Boulevard du Général Martial Valin, F-75015 Paris, France).

The official notice of the Meeting was published in the French Republic's Bulletin des Annonces Légales Obligatoires ("Bulletin of Mandatory Legal Announcements") dated

March 11^th, 2015 and contains the agenda, the draft resolutions and information on attendance and voting procedures. It can be viewed on the company's web site at: http://www.onxeo.com/eng/Investisseurs/Shareholders-Meetings.

Documents related to the meeting are available to shareholders, under the conditions set out in the current legislation, and will also be posted on the company’s website at www.onxeo.com from March 25^th, 2015 onwards.

Shareholders may, in accordance with Articles R.225-88 and R.225-89 of the French Commercial Code, consult the above-mentioned documents (together with the information specified in Articles R.225-81 and R.225-83 of the said Code) at the company's head office or request supply of the said documents and information by post/mail to a duly indicated postal/mailing or electronic address by writing to Onxeo (Direction Financière – 49 boulevard du Général Martial Valin, 75015 Paris, France), faxing to +33 1 45 58 08 81 or sending an e-mail to ag2015@onxeo.com from March 25^th, 2015 onwards.

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to "make the difference”. The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives.

Key products at advanced development stage are:
Livatag^® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive^® (Clonidine Lauriad^®): Phase II in severe oral mucositis: Positive preliminary top-line results
Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma
For more information, visit the website www.onxeo.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference Document filed with the AMF on April 7, 2014, which is available on the AMF website (http://www.amf-france.org) or on the company’s website (www.onxeo.com).